ToxGenSolutions BV (TGS)

At ToxGenSolutions BV (TGS), our mission is to revolutionize how we detect and manage debilitating diseases like Alzheimer's. We believe in the power of early diagnostic tools to change the course of health outcomes. Our microRNA diagnostics identify Alzheimer's up to at least six years before symptoms manifest, offering a significant window for intervention that could reduce both the human and economic impacts documented in recent studies. Through our technology, we're not just advancing research; we're providing real-world solutions that can alleviate the immense burden of this disease. This technology is also a game changer for pharmaceutical companies. It allows them to clearly identify which participants in their studies are at risk of developing Alzheimer's within the next six years and which are not. This clear distinction improves the design and accuracy of clinical trials, paving the way for the development of new treatments that can be applied before the disease affects patients. Our work is not just about diagnosing earlier; it’s about enabling smarter, faster development of therapies that could potentially prevent the disease altogether. “Declare the past, diagnose the present, foretell the future.” ― Hippocrates If you're interested in exploring partnership opportunities or want early access to our technology, please reach out to us at [email protected]. #ToxGenSolutions #EarlyDetection #AlzheimersResearch #AD #HealthTech #ClinicalTrials #Innovation #Diagnostics #Pharma #Biotechnology

What are #HealthTransformers like Erwin L Roggen, PhD, of ToxGenSolutions BV (TGS) saying about our #HealthMoonshot Communities? Check out hundreds of #testimonials & join us! ➡️ https://lnkd.in/gemwhQqi

Thanks to Damian Toczydłowski for highlighting this review. The role of noncoding RNAs in human evolution and therapeutic innovation is truly fascinating and promises exciting new advancements in the field. A must-read for those interested in RNA-based therapies I would say. MicroRNAs are not only key in therapeutic developments but also play an important role in early diagnostics for Alzheimer’s disease. We at ToxGenSolutions BV (TGS) can detect Alzheimer’s up to 6 years before symptoms appear using a patent-pending microRNA panel, offering a real advantage in early intervention. #microRNA #RNA #therapeutics #diagnostics #toxgensolutions

The 2024 update to the standing Lancet Commission on dementia prevention, intervention, and care adds two new risk factors (high LDL cholesterol and vision loss) and indicates that nearly half of all dementia cases worldwide could be prevented or delayed by addressing 14 modifiable risk factors.

𝗧𝗼𝘅𝗚𝗲𝗻𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝘀𝗹𝘂𝗶𝘁 𝘇𝗶𝗰𝗵 𝗮𝗮𝗻 𝗯𝗶𝗷 𝗦𝘁𝗮𝗿𝘁𝗨𝗽 𝗛𝗲𝗮𝗹𝘁𝗵'𝘀 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿 𝗠𝗼𝗼𝗻𝘀𝗵𝗼𝘁 🇳🇱 Deze samenwerking is erop gericht om de opsporing van de ziekte van Alzheimer nieuw leven in te blazen door middel van de eersteklas testservice van ToxGenSolutions BV (TGS), die een prognose biedt voor personen met een hoog risico tot 4-6 jaar voordat de eerste symptomen kunnen worden gedetecteerd. 🌍 This collaboration aims to bring new life to Alzheimer’s disease detection through ToxGenSolutions BV (TGS)'s first-in-class testing service, which provides a prognosis for high-risk individuals up to 4-6 years before the first symptoms can be detected. https://lnkd.in/e6-WfTgp

PRESS RELEASE 🗞️ ToxGenSolutions joins StartUp Health’s Alzheimer's Moonshot to revolutionize early detection with a groundbreaking 4-6 year advance window. For more information, please find the full press release attached. 🧠🚀

Game-changing news from the world of #Alzheimers research! ToxGenSolutions, a new StartUp Health company, has developed a microRNA-based test for early detection of Alzheimer's. This could revolutionize diagnosis and treatment timelines. #AlzMoonshot #HealthTransformer #HealthMoonshot Meet Erwin L Roggen, PhD, and Maria Tsamou, PhD, of ToxGenSolutions BV (TGS) ⤵️ https://ow.ly/N6lh50Sca36

Two of our esteemed customers are making waves in the health innovation space, and they're getting some well-deserved recognition in the Brightlands Maastricht Health Campus BV newsletter! Obviously we want to shine some more light on them: Dive into the first article featuring Avalanche Medical B.V. and their groundbreaking work on a durable cartilage mini-prosthesis: https://shorturl.at/oSYUA Second article highlights ToxGenSolutions BV (TGS) and their cutting edge diagnostic technology. They're predicting Alzheimer's six years before the first symptoms appear! (Dutch readers, this one's for you): https://shorturl.at/ZadAm Let's show them some love and support for their incredible contributions to healthcare innovation! 💪 #HealthTech #InnovationSpotlight #LeadingTheChange

Our CEO, Erwin L. Roggen, will be representing us at the International Conference on Neurology and Brain Disorders in Baltimore this October. The integration of AI and computational approaches is revolutionizing diagnostics and therapeutics in neurology, opening new avenues for promoting healthier aging. Interested in learning more about our innovative work? Connect with Erwin in Baltimore! #neurology #alzheimersdisease #epigenetics #ToxGenSolutions #ai #computational #diagnostics #therapeutics